tbuckley/cabot-search huggingface dataset:
Trough imatinib plasma levels in patients treated for advanced gastrointestinal stromal tumors evidence of large interpatient variations under treatment with standard doses
Authors: B. N. Bui, A. Italiano, A. Miranova, S. Bouchet, M. Molimard
Journal: Journal of Clinical Oncology (2008)

10564 Background: Large interpatient variations of trough imatinib level have been reported in patients with CML given imatinib 400- 600 mg/d; moreover, the 24h residual plasma level of imatinib was found correlated with imatinib efficacy. Methods: Trough plasma levels of imatinib were determined by high performance liquid chromatography-tandem mass spectrometry in patients with advanced GIST, seen at IB 24h (imatinib 400 mg/d) or 12h (imatinib 400 mg bid) after the last dose intake. Results: From March 2007 to October 2007, 31 dosages were performed in 24 patients. Imatinib dose was 400 mg/d (median duration 26 months), for 24 determinations, and 800 mg/d for 7 (dose increased for tumor progression in 6). There were 11 female and 13 male patients and the median age was 66 years (range: 45–90); treatment was for liver (6), peritoneal 7) metastasis or both (8); 3 patients had inoperable primaries. Mean and median trough plasma levels were 799 and 450ng/ml (range: 188–3,321) for a prescribed dose of 400 mg/d and 1,778 and 715 ng/ml (range 374–3,349) for 800 mg/d. Five patients are still responders for 5 years or more and 4/5 had imatinib levels >1000 ng/ml. The inter-patient variability was in contrast to low intra- patient variability, except in one patient whose compliance was corrected. Among 4 patients with very low levels (3 with <250 ng/ml at 400 mg/d, and 1 at 374 ng/ml at 800 mg/d), poor compliance to treatment could be suspected in 3 patients; 3 of those patients were imatinib responders. In this series, no relationship between imatinib trough plasma levels and drug interaction was found. Conclusions: In this preliminary study, large inter-patient variations of imatinib trough plasma levels were found. Very low levels suggest a bad compliance to treatment. High trough imatinib levels were found in long-term responders to imatinib. It remains to be determined whether a threshold that is correlated with optimal drug efficacy exists. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Novartis Novartis
High Rate of Deep-Vein Thrombosis in Asia after Major Orthopedic Surgery: The AIDA Study Final Results.
Authors: Franco Piovella, Ching-Jen Wang, Housan Lu, Lee Kenneth, Lai Heng Lee, Won Chul Lee, Alexander G. Turpie, Alexander Gallus, Andre Planes, Raffaella Passera, Alain Rouillon
Journal: Blood (2004)
Validation of the NCCN-IPI for Diffuse Large B-Cell Lymphoma (DLBCL) in a Nation-Wide Spanish Series of 1885 Patients. the Geltamo-IPI Project
Authors: Carlos Montalbán, Antonio Díaz-López, Heidys Garrote Santana, Julián Matias Freue, Lourdes López, Raquel De Oña, Ana M Martín Moreno, Armando López-Guillermo, Ivan Dlouhi, Jordina Rovira, Mario Rodríguez, José Maria Sánchez Pina, Sara Alonso, Alejandro Martín García, Silvana Novelli, Juan-Manuel Sancho, Olga García, Antonio Salar, Antonio Gutierrez, Mariana Bastos, Maria Rodriguez-Salazar, Ruben Fernández, Juan F. Domínguez, Jose A. Queizán, Sonia González de Villambrosia, Raúl Córdoba, Victor Abraira, Jose Rodríguez, Juan F. Garcia
Journal: Blood (2015)
Use of Mesenchymal Stem Cells To Treat Pediatric Patients with Severe (Grade III–IV) Acute Graft Versus Host Disease Refractory to Steroid and Other Agents on a Compassionate Use Basis.
Authors: Vinod K. Prasad, Kenneth G. Lucas, Gary I. Kleiner, July-An M. Talano, David Jacobsohn, Paul Szabolcs, Rod Monroy, Joanne Kurtzberg
Journal: Blood (2007)
Insomnia prevalence in an oncology patient population: an Irish tertiary referral centre experience
Authors: E.C. Harrold, A.F. Idris, N.M. Keegan, L. Corrigan, M.Y. Teo, S.T. Lim, E. Duff, M.O. Donnell, J. Kennedy, D. O'Donnell, S. Sukor, C. Grant, D. Gallagher, S. Collier, T. Kingston, A.M. O'Dwyer, S. Cuffe
Journal: Annals of Oncology (2016)
Evolving Criteria of Donor Selection for Allogeneic Transplant in Acute Myeloid Leukemia
Authors: William Arcese, Raffaella Cerretti, Laura Cudillo, Gottardo De Angelis, Benedetta Mariotti, Adriano Venditti, Francesco Buccisano, Maria Cantonetti, Ilaria Mangione, Marco Andreani, Manuela Testi, Paolo De Fabritiis, Teresa Dentamaro, Luca Cupelli, Andrea Tendas, Giuseppe Avvisati, Maria Cristina Tirindelli, Ombretta Annibali, Andrea Mengarelli, Francesco Marchesi, Atelda Romano, Anna Chierichini, Barbara Anaclerico, Agostino Tafuri, Antonella Ferrari, Virginia Naso, Silvia Miccichè, Fabio Di Piazza, Francesco Lo Coco, Sergio Amadori, Alessandra Picardi
Journal: Blood (2015)
The prostate cancer registry: Patient characteristics, treatments and preliminary outcomes from a large observational study of metastatic castration-resistant prostate cancer (mCRPC)
Authors: S. Chowdhury, A.J. Birtle, A. Bjartell, L.A.M. Costa, S. Feyerabend, L. Galli, E. Kalinka-Warzocha, G. Kramer, J.P. Maroto Rey, N. Lumen, V.B. Matveev, T. Paiss, D. Spaeth, L. Antoni, E. Klumper, R. Wapenaar, E. Lee
Journal: Annals of Oncology (2016)
Analytic validation of a clinical circulating tumor DNA assay for patients with solid tumors
Authors: P.J. Stephens, T. Clark, M. Kennedy, J. He, G. Young, M. Zhao, M. Coyne, V. Breese, L. Young, S. Zhong, M. Bailey, B. Fendler, V.A. Miller, E. Schleifman, E. Peters, G. Otto, D. Lipson, J.S. Ross
Journal: Annals of Oncology (2016)
Patient-private disease evolution and heterogeneity in bilateral breast cancer
Authors: E. Fountzila, V. Kotoula, F. Zagouri, E. Giannoulatou, G. Kouvatseas, G. Pentheroudakis, T. Koletsa, M. Bobos, K. Papadopoulou, E. Samantas, E. Demiri, S. Miliaras, C. Christodoulou, S. Chrisafi, E. Razis, F. Fostira, D. Pectasides, G. Zografos, G. Fountzilas
Journal: Annals of Oncology (2016)
Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab—a report from the BELOB trial
Authors: Renske Gahrmann, Martin van den Bent, Bronno van der Holt, René Michel Vernhout, Walter Taal, Maaike Vos, Jan Cees de Groot, Laurens Victor Beerepoot, Jan Buter, Zwenneke Hendrieke Flach, Monique Hanse, Bas Jasperse, Marion Smits
Journal: Neuro-Oncology (2017)

The current method for assessing progressive disease (PD) in glioblastoma is according to the Response Assessment in Neuro-Oncology (RANO) criteria. Bevacizumab-treated patients may show pseudo-response on postcontrast T1-weighted (T1w) MRI, and a more infiltrative non-enhancing growth pattern on T2w/fluid attenuated inversion recovery (FLAIR) images. We investigated whether the RANO criteria remain the method of choice for assessing bevacizumab-treated recurrent glioblastoma when compared with various volumetric methods. Patients with assessable MRI data from the BELOB trial (n = 148) were included. Patients were treated with bevacizumab, lomustine, or both. At first and second radiological follow-up (6 and 12 wk), PD was determined using the 2D RANO criteria and various volumetric methods based on enhancing tumor only and enhancing plus non-enhancing tumor. Differences in overall survival (OS) between PD and non-PD patients were assessed with the log-rank test and a Cox model. Hazard ratios (HRs) and their 95% CIs were determined. For all patients together, all methods (except subtraction of non-enhancing from enhancing volume at first follow-up) showed significant differences in OS between PD and non-PD patients (P < .001). The largest risk increase for death in case of PD at both first and second follow-up was found with the RANO criteria: HR = 2.81 (95% CI, 1.92–4.10) and HR = 2.80 (95% CI, 1.75–4.49), respectively. In the bevacizumab-treated patients, all methods assessed showed significant differences in OS between PD and non-PD patients. There were no significant differences between methods. In the first 12 weeks, volumetric methods did not provide significant improvement over the RANO criteria as a posttreatment prognostic marker.
MLL Fusion Proteins Directly Regulate a Small Set of Wild Type MLL Target Genes.
Authors: Qianfei Jeffrey Wang, George Wu, Shuangli Mi, Fuhong He, Jingfang Dong, Ryan J. Mattison, Joseph Kaberlein, Qianben Wang, Shyam Prabhakar, Hongkai Ji, Michael J Thirman
Journal: Blood (2009)
Converting Adult Pancreatic Islet α Cells into β Cells by Targeting Both Dnmt1 and Arx
Authors: Harini Chakravarthy, Xueying Gu, Martin Enge, Xiaoqing Dai, Yong Wang, Nicolas Damond, Carolina Downie, Kathy Liu, Jing Wang, Yuan Xing, Simona Chera, Fabrizio Thorel, Stephen Quake, Jose Oberholzer, Patrick E. MacDonald, Pedro L. Herrera, Seung K. Kim
Journal: Cell Metabolism (2017)
Interphase Fuorescence In Situ Hybridisation (iFISH) To Detect Cryptic Chromosome Defects in Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL).
Authors: Paolo Bernasconi, Paola Maria Cavigliano, Marina Boni, Irene Dambruoso, Rita Zappatore, Ilaria Giardi, Silvia Calatroni, Barbara Rocca, Monia Lunghi, Carlo Castagnola, Cesare Astori, Mario Lazzarino
Journal: Blood (2005)
Extracorporeal Photopheresis (ECP) for Acute and Chronic GVHD, a Report of 56 Patients Treated in a Single Institution.
Authors: Eldad J. Dann, Alla Badian, Tselestina Stravets, Elena Kertsman, Irit Avivi, Ronit Elhasid, Nuhad Haddad, Riva Fineman, Tsila Zuckerman, Ana Oliven, Lilah Bonstein, Jacob M. Rowe
Journal: Blood (2004)
Interim safety results from the phase 2 ABOUND.PS2 study evaluating nab-paclitaxel (nab-P) + carboplatin (C) followed by nab-P monotherapy in patients (pts) with NSCLC and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2
Authors: A. Gajra, H. Ali, K.I. Amiri, N. Abdel Karim, M.R. Matrana, D. Mulford, T.J. Ong, A. Sanford, E. Santos, M. Socinski, D.R. Spigel, R.C. Lilenbaum
Journal: Annals of Oncology (2016)
Disruption of Bcl-2 Heterodimerization by the BH3 Mimetic ABT-737 Restores Spontaneous Apoptosis and Induces Differentiation in High Risk MDS and AML.
Authors: L. Ades, S. Boehrer, T. Braun, J. Grosjean, C. Fabre, Pierre Fenaux, Guido Kroemer
Journal: Blood (2007)
Superior Complete Response Rate and Progression-Free Survival after Autologous Transplantation with up-Front Velcade-Thalidomide- Dexamethasone Compared with Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma
Authors: Michele Cavo, Paola Tacchetti, Francesca Patriarca, Maria Teresa Petrucci, Lucia Pantani, Michela Ceccolini, Monica Galli, Francesco Di Raimondo, Claudia Crippa, Elena Zamagni, Patrizia Tosi, Franco Narni, Sara Bringhen, Vittorio Montefusco, Massimo Offidani, Silvia Buttignol, Anna Levi, Ausilia Gorgone, Annamaria Brioli, Maria Caterina Pallotti, Tonino Spadano, Norbert Pescosta, Luca Baldini, Antonio Ledda, Tommaso Caravita, Antonietta Falcone, Alfonso Zaccaria, Giulia Perrone, Alessandro Petrucci, Antonio Palumbo, Mario Boccadoro, Michele Baccarani
Journal: Blood (2008)
Low-Dose Dasatinib as Front-Line Therapy for Elderly (&gt; 60 Years) Patients with CML
Authors: Raffaele Porrini, Enrico Montefusco, Roberto Latagliata, Massimo Breccia, Paolo Vigneri, Luigia Luciano, Antonella Gozzini, Fausto Castagnetti, S. Ulisciani, Francesco Cavazzini, M. Annunziata, F. Sora', Antonella Russo Rossi, Patrizia Pregno, Malgorzata Monika Trawinska, E. Crisa', Pellegrino Musto, Mario Tiribelli, G. Binotto, U. Occhini, C. Feo, Bruno Martino, Paolo Avanzini, E. Spina, Fabrizio Pane, Valeria Santini, Gianantonio Rosti, Giovanna Rege Cambrin, Giuliana Alimena
Journal: Blood (2010)
genitourinary tumours, prostate Final overall survival (OS) from the AFFINITY phase 3 trial of custirsen and cabazitaxel/prednisone in men with previously treated metastatic castration-resistant prostate cancer (mCRPC)
Authors: K. Fizazi, S.J. Hotte, F. Saad, B. Alekseev, V.B. Matveev, A. Flechon, G. Gravis, F. Joly, K.N. Chi, Z. Malik, P. Stewart, C. Jacobs, T.M. Beer
Journal: Annals of Oncology (2016)
Biomolecular, biochemical, and radiologic evaluation and safety of chemotherapy with bevacizumab in treatment of patients affected by mCRC.
Authors: L. Rossi, E. Veltri, M. Colonna, F. Zoratto, S. Vari, M. Mottolese, M. Di Seri, A. Romiti, F. Longo, D. Giannarelli, S. Tomao
Journal: Journal of Clinical Oncology (2011)

e14140 Background: Bevacizumab (BEV) combined with chemotherapy prolongs PFS and OS in treatment of mCRC regardless of KRAS status. This study investigated statistical significance of BEV clinical benefit (CB) in treatment of mCRC according to KRAS status and metastatic sites.We evaluated timing of response through correlation between tumor markers values (MKS) and clinical responses. Most severe toxicities were observed. Methods: 108 patients were treated with first-line Folfiri or FolFoX and BEV. KRAS status was detected. Before therapy patients were investigated with CT scan and with blood sample to define MKS; MKS after 2 months of chemotherapy and CT scan after 3 months were performed. Statistical analysis has benefited from chi-square test. Results: Overall response rate (RR) of 42% and CB of 82% were obtained, with correlation between MKS and clinical response of 90%. 49% of population presented only hepatic metastases while 51% showed multiple metastatic sites. RR in exclusive hepatic metastatic group was 48% vs 35% multiple metastatic sites (p=0.15), CB was 90% vs 71% respectively (p=0.01). KRAS mutations were investigated in 100 patients. 65 patients were wild-type (wt 65%) while 35 patients were mutated (mut 35%). RR in wt group was 51% vs 29% in mut (p=0.03), while CB was 86% vs 80% respectively (p=0.42). Correlation between MKS and clinical response was 91% in wt group vs 93% in mut. 72 patients (66%) experienced any grade toxicities. Most common G3-G4 toxicities were neutropenia (16%), diarrhea (4%) and vomiting (2%). G1-G2 BEV toxicities were bleeding (13%), hypertension (10%), deep vein thrombosis (5%), proteinuria (2%) and pulmonary embolism (1%); no G3-G4 toxicities were showed. Conclusions: RR in KRAS groups was different with an advantage, statistical significant, in KRAS wt, but this difference does not observe in CB. BEV provides significant RR and CB after short time of treatment and MKS are optimal parameters of early clinical response. BEV provides statistical significant CB in patients with only hepatic metastases vs patients with multiple metastatic sites. Treatment with BEV was well tolerated.
Clinical Evidence of Disease Anticipation in Families Segregating a <i>C9orf72</i> Repeat Expansion
Authors: Sara Van Mossevelde, Julie van der Zee, Ilse Gijselinck, Kristel Sleegers, Jan De Bleecker, Anne Sieben, Rik Vandenberghe, Tim Van Langenhove, Jonathan Baets, Olivier Deryck, Patrick Santens, Adrian Ivanoiu, Christiana Willems, Veerle Bäumer, Marleen Van den Broeck, Karin Peeters, Maria Mattheijssens, Peter De Jonghe, Patrick Cras, Jean-Jacques Martin, Marc Cruts, Peter P. De Deyn, Sebastiaan Engelborghs, Christine Van Broeckhoven
Journal: JAMA Neurology (2017)

<h3>Importance</h3> Patients carrying a<i>C9orf72</i>repeat expansion leading to frontotemporal dementia and/or amyotrophic lateral sclerosis have highly variable ages at onset of disease, suggesting the presence of modifying factors. <h3>Objective</h3> To provide clinical-based evidence for disease anticipation in families carrying a<i>C9orf72</i>repeat expansion by analyzing age at onset, disease duration, and age at death in successive generations. <h3>Design, Setting, and Participants</h3> This cohort study was performed from June 16, 2000, to June 1, 2016, in 36 extended Belgian families in which a<i>C9orf72</i>repeat expansion was segregating. The generational effect on age at onset, disease duration, and age at death was estimated using a mixed effects Cox proportional hazards regression model, including random-effects terms for within-family correlation and kinship. Time until disease onset or last examination, time from disease onset until death or last examination, or age at death was collected for for 244 individuals (132 proven or obligate<i>C9orf72</i>carriers), of whom 147 were clinically affected (89 proven or obligate<i>C9orf72</i>carriers). <h3>Main Outcomes and Measures</h3> Generational effect on age at onset, disease duration, and age at death. <h3>Results</h3> Among the 111 individuals with age at onset available (66 men and 45 women; mean [SD] age, 57.2 [9.1] years), the mean (SD) age at onset per generation (from earliest-born to latest-born generation) was 62.5 (8.3), 57.1 (8.2), 54.6 (10.2), and 49.3 (7.5) years. Censored regression analysis on all affected and unaffected at-risk relatives confirmed a decrease in age at onset in successive generations (<i>P</i> &lt; .001). No generational effect was observed for disease duration or age at death. <h3>Conclusions and Relevance</h3> The clinical data provide supportive evidence for the occurrence of disease anticipation in families carrying a<i>C9orf72</i>repeat expansion by means of a decrease in age at onset across successive generations. This finding may help clinicians decide from which age onward it may be relevant to clinically follow presymptomatic individuals who carry a<i>C9orf72</i>repeat expansion.
Dose intensity of cisplatin and gemcitabine (CG) for muscle invasive urothelial bladder cancer (MIUBC) in the neoadjuvant versus adjuvant settings: The Fox Chase Cancer Center (FCCC) experience
Authors: J. H. Hoffman-Censits, Y. Wong, T. Li, S. Boorjian, V. N. Giri, R. Uzzo, R. E. Greenberg, G. Hudes, D. Y. Chen
Journal: Journal of Clinical Oncology (2009)

e16012 Background: Despite radical cystectomy (RC), subjects with MIUBC remain at risk of recurrence and optimal timing of chemotherapy remains unclear. Historically, we offered adjuvant (ADJ) CG to patients (pts) with T≥3 or node positive tumors. Since Dec 2005, neoadjuvant (NEO) CG treatment has been our preferred approach for pts with ≥T2 tumors. We compare our results with NEO and ADJ CG, including pathologic response after NEO CG. Methods: We reviewed records of patients who underwent RC for MIUBC and received at least 2 cycles of perioperative CG between Jan 2002 and Dec 2008at FCCC. We used Fisher's exact and Wilcoxon tests, as well as Generalized Estimating Equations (GEE), to compare baseline patient characteristics, dose intensity, completion, and complication rates in the ADJ and NEO groups. Results: Results of 22 ADJ and 17 NEO patients are shown below. Characteristics of age, gender, race, preop T stage and ECOG performance status (PS) ≤1 were similar. There was no significant difference in preoperative T stage between groups (p=0.2). The delivery of full doses (C 70mg/m 2 ,G 1000 mg/m 2 ) of GC were similar in the NEO vs the ADJ group. The delay between RC and chemotherapy may be shorter in the patients treated preoperatively, and trended toward significance (p=0.06). Reasons for dose modifications and delays are also shown in the Table . Of pts treated with NEO CG, 10/17 (55.7%) were ≤pT1 with 9 of those 10 pts also pN0 (52.9% of 17 pts) . 5/17 (29.4%) had positive lymph nodes at RC. Conclusions: CG for MIUBC is well tolerated in the NEO setting, with dose intensity comparable to that delivered adjuvantly. NEO pathologic downstaging with CG appears comparable to historical results with MVAC, and should be confirmed in larger, prospective studies. [Table: see text] No significant financial relationships to disclose.
The London OMED position statement for credentialing and quality assurance in digestive endoscopy
Authors: D. Faigel, P. Cotton
Journal: Endoscopy (2010)

Correction to: The London OMED position statement for credentialing and quality assurance in digestive endoscopyEndoscopy 2009; 41(12): 1069-1074DOI: 10.1055/s-0029-1215279
Dose-Dense CHOP Plus Rituximab (R-CHOP14) Seems To Overcome, in Large B Cell Lymphoma, the Negative Prognostic Significance of B Cell Origin.
Authors: Luigi Rigacci, Luca Nassi, Simonetta di Lollo, Benedetta Puccini, Morena Doria, Silvia Mappa, Gloria Capaccioli, Renato Alterini, Valentina Carrai, Alberto Bosi
Journal: Blood (2007)
Promoter and Exon 1 Hypermethylation of the Tumor Suppressor Gene PRDM1/Blimp-1 indicates Its Pathogenetic Role in EBV-Positive Burkitt Lymphoma,
Authors: Kui Nie, Taotao Zhang, Carlos E Bacchi, Eduardo Queiroga, Dra. Gabriela Gualco, Jiong Yan, Yifang Liu, Sharon Barouk, Attilio Orazi, Daniel M Knowles, Wayne Tam
Journal: Blood (2011)
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma: Randomized phase 3 KEYNOTE-204 study
Authors: P.L. Zinzani, J. Kline, R. Chen, V. Ribrag, G. Salles, I. Matsumura, Y. Zhu, A. Ricart, A. Balakumaran, M. Fanale
Journal: Annals of Oncology (2016)
The Limited Role of Psychotherapy In Torsion Dystonia
Authors: Roswell Eldridge
Journal: JAMA (1969)

The number of physicians consulted before diagnosis and the results of psychiatric treatment were recorded for 44 patients in whom torsion dystonia (TD) developed. Twenty-three of these patients saw six or more physicians before the diagnosis was established. This probably reflects the absence of any single physical or biochemical abnormality characteristic of the hereditary dystonias and the general unfamiliarity of the medical profession with these diseases. Of the 24 patients who had a trial of psychotherapy, seven reported that their general condition was made worse, 12 reported no effect, and five reported benefit in emotional status but not in dystonic symptoms. In three helped by psychotherapy, the diagnosis of TD had already been made and treatment was aimed, not at curing the movement disorder, but at assisting the patient and family to adjust to the disease.
NCOG-16. IDENTIFYING COGNITIVE IMPAIRMENT IN PATIENTS WITH PRIMARY MALIGNANT BRAIN TUMORS (PBMT)
Authors: Jason Weimer, Susan Misko, Jan Drappatz, Frank Lieberman, Heidi Donovan, Paula Sherwood, Terri S. Armstrong
Journal: Neuro-Oncology (2016)

Cognitive impairment is one of the most disabling symptoms for individuals with PBMTs and has been identified as a major source of psychological distress by caregivers. Domain specific data regarding cognitive dysfunction following surgery is primarily from research conducted prior to the advent of current standards of care. The aims of this analysis were to identify specific domains of cognitive function most affected in the post-operative/treatment phases and to examine predictors of poor performance in those domains using a selected battery of neuropsychological tests. Neuropsychological assessments were performed by trained examiners on patients (n=86) with a PMBT diagnosis that were recruited as part of a caregiver intervention trial (R01-NR013170). Domain-specific z-scores were created using published normative data for matching age groups and analyzed using Pearson’s Chi-square and paired t-tests to evaluate univariate associations between age, gender, tumor location, type, grade and treatment status as potential predictors of cognitive impairment. Participants were mostly male (59.2%), middle aged (mean 54.4, SD 15), with glioblastomas (55.4%) in the middle (40.8%) or frontal (35.4%) areas of the brain. The majority of participants had surgery (88.8%), chemo (62.3%), or radiation (65.6%) prior to assessment. Participant mean domain scores for Executive Function (z=-1.8), Verbal Memory (z=-1.5) and Aphasia (z=-0.8) fell below normative values indicating cognitive impairment. Age was significantly associated with impairment in Executive Function (p =.004) and Verbal Memory (p=.06). Further details of tumor type, location, and genetics will be discussed. This analysis shows that older patients with PMBTs are at particular risk for developing cognitive impairment in the specific areas of executive function and verbal memory. Clinicians should be aware of these risk factors, screen patients regularly for cognitive dysfunction in these areas and provide guidance to family caregivers on strategies to reduce the psychological distress associated with these impairments.